METHODS: A sample of 314 participants, predominately with moderate-to-severe OSA, were enrolled and instructed to use an OA every night. At baseline and one-year follow-up, polygraphic recordings and questionnaires, including sleepiness (measured using the Epworth sleepiness scale) and quality-of-life (measured using the Functional Outcomes of Sleep Questionnaire), were collected.
RESULTS: Among the 314 participants, 192 completed the one-year evaluation: 51 females (27%) and 141 males (73%). Overall, OA treatment resulted in 78% and 77% responders among females and males, respectively. Neither the difference in improvement nor the absolute change in AHI differed significantly based on gender, at any OSA severity level. There were no significant gender differences in sleepiness or quality of life. Treatment-related adverse reactions were more common among females.
CONCLUSIONS: Both females and males with OSA respond well to OA therapy, with nonsignificant gender differences in outcomes. Thus, the hypothesis that females respond better to OA treatment is rejected.
方法:314名参与者的样本,主要是中度至重度OSA,被登记并指示每晚使用OA。在基线和一年随访时,测谎仪录音和问卷调查,包括嗜睡(使用Epworth嗜睡量表测量)和生活质量(使用睡眠功能结果问卷测量),被收集。
结果:在314名参与者中,192人完成了为期一年的评估:51名女性(27%)和141名男性(73%)。总的来说,OA治疗导致女性和男性中78%和77%的应答者,分别。AHI的改善差异和绝对变化均不因性别而异,在任何OSA严重程度。在嗜睡和生活质量方面没有显著的性别差异。治疗相关不良反应在女性中更为常见。
结论:女性和男性OSA患者对OA治疗反应良好,结果无显著性别差异。因此,女性对OA治疗反应更好的假说被拒绝.